TABLE 2

Activities of plazomicin and comparator agents tested against Enterobacteriaceae isolates

Organism group (no. of isolates tested) and antimicrobial agentMIC50 (μg/ml)MIC90 (μg/ml)MIC range (μg/ml)% S using CLSI breakpointsa% S using EUCAST breakpointsa
Enterobacteriaceae (4,362)
    Plazomicin0.52≤0.06–>128
    Amikacin14≤0.25–>3298.998.0
    Gentamicin0.54≤0.06–>890.389.2
    Tobramycin0.54≤0.12–>890.387.1
    Ceftazidime0.1216≤0.015–>3287.985.4
    Meropenem0.030.06≤0.015–>3297.697.9
    Piperacillin-tazobactam216≤0.5–>6492.089.2
    Colistin≤0.5>8≤0.5–>884.0
    Tigecycline0.251≤0.06–499.0b95.7
    Levofloxacin≤0.12>4≤0.12–>482.979.5
CRE (97)
    Plazomicin0.51≤0.06–>128
    Amikacin16320.5–>3264.946.4
    Gentamicin2>80.12–>856.750.5
    Tobramycin>8>80.12–>813.411.3
    Ceftazidime>32>3216–>320.00.0
    Meropenem16>321–>322.17.2
    Piperacillin-tazobactam>64>6432–>640.00.0
    Colistin≤0.5>8≤0.5–>878.1
    Tigecycline0.510.12–2100.0b94.8
    Levofloxacin>4>4≤0.12–>418.611.3
Isolates carrying blaKPC genes (87)
    Plazomicin0.251≤0.06–>128
    Amikacin16320.5–>3263.242.5
    Gentamicin4>80.12–>855.248.3
    Tobramycin>8>80.12–>811.59.2
    Ceftazidime>32>324–>321.10.0
    Meropenem16>320.5–>323.410.3
    Piperacillin-tazobactam>64>6464–>640.00.0
    Colistin≤0.5>8≤0.5–>878.2
    Tigecycline0.510.12–2100.0b96.6
    Levofloxacin>4>4≤0.12–>414.99.2
Carbapenemase-negative isolates (26)
    Plazomicin0.510.12–2
    Amikacin4160.5–3292.384.6
    Gentamicin1>80.25–>869.269.2
    Tobramycin2>80.25–>857.750.0
    Ceftazidime>32>320.25–>3219.215.4
    Meropenem2320.03–3223.153.8
    Piperacillin-tazobactam>64>641–>6419.215.4
    Colistin≤0.5>8≤0.5–>875.0
    Tigecycline0.520.06–2100.088.5
    Levofloxacin2>4≤0.12–>450.034.6
  • a Criteria reported by the CLSI (14) and EUCAST (15). S, susceptible.

  • b Breakpoints from the FDA website (16).